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INTRODUCTION  
 
Advocate consultations are increasingly becoming the rule, not the exception in the HIV 
prevention research field.  As an increasing number of Phase III trials enter the field, research 
groups are seeking new ways to collaborate with advocates and maximize civil society input and 
engagement.  
 
The Advocates’ Consultation for HIV Prevention Trials: Carraguard and VOICE studies 
provided leaders from African NGOs on the frontlines of the epidemic a unique opportunity to 
learn about the clinical trial process from beginning to end, and to collectively identify ways to 
influence how scientific research is formulated.  
 
Participants represented a wide range of advocacy groups from Southern African countries, 
including advocates working in women’s health, treatment access, gender-based violence, legal 
and regulatory issues, human rights and PLWHA groups.  The strong diversity allowed for lively 
and healthy debate and many opportunities for cross learning. 
 
The consultation focused on two HIV prevention trials: the recently completed Carraguard 
microbicide trial by the Population Council and the upcoming Vaginal and Oral Interventions  
to Control the Epidemic (VOICE) study by the Microbicide Trials Network (MTN), which  
will evaluate a candidate microbicide gel and oral  
pre-exposure prophylaxis (PrEP).  Both trials are 
focused on preventing sexual transmission of HIV 
in women. 
 
The two-day consultation was divided into three 
sections.  The first day focused on building HIV 
prevention research literacy amongst the advocates, 
enhancing their understanding of how clinical trials 
are developed and discussing ways to actively 
engage advocates in the ongoing process from trial 
protocol development to results dissemination. 
 
The second day provided an opportunity for 
advocates to contextualize this learning on key 
issues surrounding the scientific design of the 
clinical trials, rooted in the specifics of the 
Carraguard and VOICE studies.  
 
This report is divided into four sections:  
 
1. Key issues in HIV prevention research advocacy 
2. The Carraguard Study and its upcoming results  
3. Developing the VOICE Study  
4. Next Steps: Recommendations and action items  
KEY TERMS: 
 
Microbicide: Any substance, such as a gel or 
cream that can substantially reduce the risk of 
acquiring HIV through sex, when it is applied to 
the vagina or rectum.  
 
PrEP: Pre-exposure prophylaxis is an 
experimental strategy where one or more of the 
ARV drugs normally used for AIDS treatment is 
taken by HIV negative individuals in the hope of 
preventing HIV.  
 
Randomized clinical trial: These studies test if 
an experimental product works by dividing 
participants by chance into two or more groups, 
and comparing the group given the active 
product with a group made up of similar people 
who have been given a placebo, a product that 
looks like the experimental product but lacks the 
active component.  
 
Trial protocol: The document that lays out the 
particulars of a trial including the question the 
study is trying to answer, the trial design, criteria 
for participation, and the care provided to 
participants.  
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KEY ISSUES IN HIV PREVENTION RESEARCH ADVOCACY 
 
Key issues raised during the consultation reflected both long-standing concerns of advocates, 
including standard of care for participants and ethical considerations in trial design, as well  
as emerging scientific and social issues, such as potential for resistance with ARV-based 
microbicides.  The following section highlights the main issues that came up for advocates  
and activists during the consultation.  
 
Community involvement: The consultative time line and process  
 
Strengthening community engagement is an ongoing process in the HIV prevention and 
microbicides field.  While lack of communication and meaningful involvement are still 
problematic at times, participants acknowledged an improvement and pointed to consultations 
such as these as a welcome and much-needed part of the process.  Advocates accepted their share 
of responsibility for educating themselves, staying engaged and accessing information that is 
readily available.  
 
At which point in a protocol’s development should advocates be engaged was also discussed. 
Some participants felt the consultative process should start very early, perhaps as early as the 
concept development phase, and carry through to results dissemination.  However, others noted 
that overly extensive consultation could prove burdensome to advocates, and their time and skills 
should be utilized strategically.  
 
Research literacy, training and information dissemination  
 
HIV prevention research is complicated, both scientifically and ethically.  Advocates and 
researchers alike have recognised an urgent need to conduct trainings for advocates to build and 
strengthen their scientific research literacy.  Participants were eager to identify opportunities to 
incorporate information on microbicides and PrEP trials into existing training programs on HIV 
prevention, women’s issues and gender-based violence, such as those run by South Africa’s 
Treatment Action Campaign and Gender AIDS Forum.  
 
But training is only one piece of the puzzle.  Advocates emphasized the importance of regular 
information dissemination to their groups.  This would help ensure advocates are well prepared 
for unexpected announcements and the official release of trial results, especially when they are 
called upon by the media to comment.  
 
When the Cellulose Sulfate microbicide trial closure in South Africa led to sensationalised news 
coverage by local newspapers, advocates helped to set the record straight and played a critical 
role in “damage control.”  
 
Ensuring advocates receive proper training and remain well informed can assist scientists and 
research groups.  As members of the research communities, advocates often know the best ways 
to reach their communities, deal with negative media situations and help research groups develop 
effective communication strategies.  
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Funding advocacy groups without compromising them 
 
One advocate pointed to the disjuncture between the “paid” work of science and the often 
“voluntary” nature of advocacy.  Lack of resources often makes it difficult for advocates to 
improve and expand upon their work in communities.  While prevention research trials are  
seeing increased budget for community outreach and results dissemination, more funding  
may be required for independent advocacy groups to be able to disseminate information more 
effectively, especially at the grassroots level.  
 
This begs the question, who pays? 
  
There is a fine line to balance when considering if research organizations should finance external 
advocacy work.  While everyone agreed that consultative processes funded by research groups 
are necessary, few were comfortable with the idea of research organizations funding civil society 
groups directly.  Receiving direct funding from researchers could hinder civil society’s 
independent watchdog mandate and potentially create conflicts of interest.  
 
Instead, private and public donors must be encouraged to contribute more funds for advocacy 
purposes.1  It was also suggested that advocates should include provisions for microbicide 
advocacy into existing funding proposals.  This would allow advocacy groups to integrate 
microbicides-related activities into their broader strategic work plans and enable local leadership 
of organizations to determine their own priorities. 
 
Finding a product that is effective and practical  
        
As more research is conducted,  
microbicide candidates are becoming  
more sophisticated. Early microbicide 
candidates are non-specific to HIV and  
must be used close to the time when people 
had sex.  For example, Carraguard, one  
of the first products to enter large-scale  
trials, is based on a natural product, 
carregnein, from seaweed.  Newer  
studies, including VOICE, are beginning 
to test products that contain anti-retroviral 
drugs, gels known as ARV-based 
microbicides.  
  
Different products employ different ways to protect the body from HIV infection.  How a 
product works is referred to as its “mechanism of action.” The table above summarizes 
                                                
1 One possibility that the Global Campaign for Microbicides is exploring is the establishment of a “funding 
window” within a professional grant-making entity that would faciliate access to easily accessible small grants for 
national, regional or local advocacy groups for this kind advocacy work. Such a mechanism could help bridge the 
gap between the needs of smaller organizations for capacity building and advocacy funding and their access to more 
substantial funding from other sources.  
 
How microbicides might work 
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the main “mechanisms of action” of microbicide candidates currently being tested.  The 
future may bring products that include combination microbicides.  These products may 
use multiple mechanisms of actions simultaneously, which could potentially offer more 
protection than one product used alone.  This research remains to be done. 
 
Finding a product that is safe and effective at preventing HIV transmission is critical.  It is also 
essential to find a product that is acceptable and feasible for women to incorporate into their 
daily lives.  
 
A product could prove effective in the context of a clinical trial—meaning that it is scientifically 
safe and has the ability to prevent HIV when used consistently and properly.  However, if for 
example, the product is required to be used within 30 minutes of sex or must be refrigerated, 
women in the “real world” may find its use impractical. 
  
The goal is to find a product that is efficacious—meaning it is reasonably effective at reducing 
HIV risk within real-world settings.  With this in mind, scientists are exploring products with 
different dosing strategies that may be more practical and effective.  For example, the VOICE 
study will evaluate approaches in which women will use the product once daily independent of 
when they have sex.  
 
We need products that meet the standards of scientists and the needs of the women.  
 
Standard of prevention and care for participants 
 
Everyone agreed that better meeting the needs of trial participants, from receiving a high-quality 
prevention package to ensuring care and treatment services for participants who sero-convert 
during the study, was a high priority.  The group openly discussed raising the standard of 
prevention services, including requests that free female condoms, hormonal contraceptive and 
pap smears be included in the VOICE protocol and made available at all sites. These demands 
for services are not unique to the VOICE study.  They are increasingly being asked of many HIV 
prevention research studies.  
 
Post-trial access issues 
 
It is never too early to discuss post-trial access to products once they have been shown to be 
effective.  Many treatment activists who have led the charge in making anti-retroviral treatment 
available for people living with HIV/AIDS in Africa were concerned about regulatory issues, 
licensing an effective product in Africa, and making sure a proven product will be accessible and 
affordable to the people who need it most.  
 
Although many questions were left unanswered, an important dialogue was launched.  Most 
importantly, the research teams were ready to engage, and committed to working with the 
advocates to find the answers together. 
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THE CARRAGUARDTM STUDY AND ITS UPCOMING RESULTS 
 
Population Council was represented by presentors, Sumen Govender, clinical study manager, 
Khatija Ahmed, principal investigator, Setshaba Research Centre, and Malebo Rathlagana, 
microbicides trial community outreach team member, Setshaba Research Centre.  
 
Population Council began its Microbicide Programme in the late 1980’s, and has been testing the 
microbicide candidate Carraguard or similar carrageenan formulations for more than ten years. 
The research group has held a handful of advocate and community consultations similar to this 
one, all of which have informed their clinical trials and interactions with local communities.2 
 
During this consultation, members of the Carraguard trial team provided background about the 
product and the trial.  They shared their plans for disseminating results in South Africa and 
globally.  The following section covers the main issues discussed in regard to the possible 
outcome scenarios of this clinical trial and the implications they could have on the microbicides 
research field and potentially for HIV prevention and women around the world.  
 
What is the microbicide product, Carraguard? 
 
Carraguard is the Population Council’s lead candidate, and one of the earliest microbicide 
products to be tested in a large-scale study.  It is made from carrageenan, which is made from 
seaweed.  Carrageenan is generally recognised as safe3 and is currently used as a thickener in 
many products found on the market.  Qualities that make it an ideal candidate for a microbicide 
are:  
• It is not likely to be absorbed into the bloodstream via vaginal use 
• It is odourless, tasteless, and colourless in its microbicide form  
• It is inexpensive, stable, and widely available  
 
The Carraguard Phase III Study  
 
The Carraguard Phase III, large-scale efficacy trial included over 6,000 trial participants at three 
sites in South Africa: Gugulethu (Cape Town), Soshanguve (Pretoria) and Isipingo (Durban).4  
The trial was designed to evaluate the efficacy and long-term safety of the candidate microbicide 
Carraguard for preventing male-to-female sexual transmission of HIV.  The study was completed 
31 March 2007, and results are expected in February 2008.  Carraguard was the first novel 




                                                
2 The Population Council hosted consultations bringing together advocates and scientists – one in 1997 and one in 
1998 – in South Africa to gather input on the protocol before starting the Phase 2 trial. Population Council has 
included budgets for community consultations during their Phase III study to support the community advisory 
groups at the two sites that chose to have them. At their third site at the Medical Research Council, regular 
interactions with the community have taken place.  
3 Generally Recognized As Safe (GRAS) is an official designation given by the US Federal Drug Administration. 
4 The study was conducted in collaboration with the South African Medical Research Council, the University of 
Cape Town, and the University of Limpopo/Medunsa campus. 
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Recruiting trial volunteers 
 
Population Council invested a lot of energy in developing new tools for the Carraguard study to 
strengthen the informed consent process.  The team shared the study’s informed consent forms 
and a 20-minute video developed and used at the trial sites to educate potential volunteers about 
the study.  
 
While most of the advocates found the video interesting and useful in explaining the study and 
what a microbicide is, some raised issues with the use of the traditional healer in the video.  The 
video has been pre-tested in the trial communities and reviewed by community advisors.  Still, 
the differences in opinions voiced during the consultation underscore that what may work in one 
community with a group of constituents may not work for another group. 
 
Additionally, advocates suggested that, in order to add weight to the informed consent process, 
educational videos, facilitated by recruitment officers, could be shown on televisions in the 
waiting rooms.  In fact, these activities did take place during the trial.5  
 
Ensuring quality of prevention services, prevention services, sexuality and STI counselling  
 
The health services provided at clinical trial sites often surpass services available in the public 
sector in resource-limited settings.  This disparity presents challenges for researchers, as some 
women get screened simply to find out their sero-status or receive free STI screening.  As some 
regions report as high as 50% of women screening out, this presents an incredible burden on the 
sites and their recruitment efforts.  
 
Despite these pressures, trial sites must be held to the high standards of services as outlined in 
their study protocols and committed to the research communities.  For example, one participating 
advocate who was also a trial participant in a separate study shared her personal experience.  She 
told the group that there was inadequate STI and sexuality counselling at the Gugulethu research 
centre she attended.  She also revealed that condoms were not given to women at this site and 
that her health care worker did not demonstrate how to insert the microbicide applicator 
properly, as they are supposed to do.  
 
Astonished by this testament, the investigators from the Population Council assured the group 
that under no circumstances was this kind of service acceptable, nor likely, and promised to 
follow up.  This scenario highlights the need for advocates and researchers alike to maintain 
close ties at the site level and to ensure sites are providing the quality of services and provision 
of care they promise to uphold. 
Issues around results dissemination  
 
Population Council plans to release the results to the public in February 2008 in advance of the 
upcoming Microbicides 2008 Conference in India.  The timing of the release of results was 
                                                
5 All three Population Council sites showed educational videos in their waiting rooms throughout the trial, as well as 
bringing in speakers to talk to women about healthcare.  
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discussed extensively.  It was agreed that a multi-pronged approach is needed and that 
researchers need to be aware of advocates’ information needs.  Some advocates who often serve 
as media spokespersons for their groups felt it was critical to be briefed confidentially in advance 
of the public announcement to help prepare them to talk with the media.  
 
These negotiations are often tricky, as the trial has responsibilities to communicate the results to 
their trial participants, government officials, and funders first.  Still, advocates have a stake in the 
results, and the group discussed ways to strike a balance between respecting the embargo and 
preventing leaks while preparing stakeholders to communicate the results to the public.  
 
If the results are positive: Steps to getting the 
product on the shelf 
 
If Carraguard releases significant results 
indicating the product is 40-60% effective at 
reducing women’s risk to sexually-transmitted 
HIV infection, Population Council will work 
urgently and closely with regulatory bodies to 
get Carraguard registered and licensed in South 
Africa, where the trial took place, and the 
world.  
 
Advocates have a key role to play in 
facilitating the regulatory process, especially in 
countries like South Africa, where the urgent 
need is often challenged by tedious processes.  
 
Advocacy can also occur around the threshold 
for efficacy, and advocates should hold 
research groups accountable for its decisions 
around which products they push through the 
pipelines, and the regulatory process.  
 
If proven effective, Population Council is committed to getting Carraguard to market at the 
lowest price possible.  The research group would consider licensing the product to 
pharmaceutical companies to manufacture, but Population Council would retain intellectual 
property rights, helping to ensure their continued ability to work toward universal access to 
women.  
 
If the Carraguard results reveal that the product is not an effective microbicide, the field 
nonetheless has learned, and will continue to learn much from this trial.  Regardless of the  
results, this trial clearly shows that this much-needed research takes time, money, and a  
strong commitment to the research process. 
How good is “good enough”? 
 
The Carraguard study was designed to be able to see 
if there was at least a 33% difference in the number 
of HIV infections between the Carraguard group and 
the placebo group.  The study enrolled more than 
6,000 women because statistically, that is how many 
women would be needed to show a significant 
difference between the incidence of HIV in the 
placebo group and 1/3 fewer infections in the 
Carraguard arm.  
 
The study was designed to show 40-60% 
effectiveness, which means the product could offer 
significant protection, but would not offer 100% 
protection.  
 
If a product shows only a 10% effect, this means the 
results were not “statistically significant” and could 
be attributed to chance or other factors. Here, the 
study would have shown “no harm, no effect”—
meaning that although the product is not harmful to 
use, it also does not offer protective benefit to 
women.  
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DEVELOPING THE VOICE STUDY:  
 
Study presentations by: Sharon Hillier, MTN principal investigator; Ian McGowan, MTN co-
investigator; Mike Chirenje, VOICE Study co-chair; and John Mellors, MTN Virology Core 
Director. Jeanne Marrazzo, VOICE Study co-chair, participated in discussion but did not present.  
 
The newly formed research group, Microbicide Trials Network, is planning the Vaginal and Oral 
Interventions to Control the Epidemic (VOICE) study.  The VOICE study has not begun to enrol 
volunteers yet, and in fact, is still in the early stages of developing their trial design and 
protocol—guidelines for running the study.  However, the study team felt it was important to 
consult with advocates at this early stage to inform civil society groups about their plans and get 
input early in the trial design process to ensure the trial they develop meets the needs of the trial 
communities.  
 
Advocates were given the most current version of the protocol, and requested by the trial team  
to review it and provide comments.  This level of engagement at this early stage in trial 
development is setting a new precedent in the prevention research field, and advocates welcomed 
the change as a step in the right direction.  
 
The following sections reflect some of the key issues raised around the VOICE study, and 
specific challenges surrounding researching ARV-based microbicides and PrEP.  
 
The VOICE Study 
 
The VOICE Study is the first study to  
evaluate the safety and efficacy of both oral 
pre-exposure prophylaxis (PrEP) and an ARV-
based microbicide gel for prevention of sexual 
transmission of HIV in women.  VOICE is 
designed as a five-arm, double-blinded  
study in which women are first randomized 
to receive either microbicide gel or oral  
PrEP, and then within each group,  
randomly assigned to either  
tenofovir  topical gel or  
placebo gel; or to oral tenofovir, 
oral Truvada or oral placebo.  
 
Currently, the study plans to enrol 4,200 women at 10 sites in South Africa, Malawi, Uganda, 
Zambia and Zimbabwe.6  Women will use study product—either gel or oral tablet—once a day.  
In addition to evaluating safety and effectiveness of the two approaches, researchers also will 




                                                
6 The consultation included advocates from all of the proposed VOICE trial site countries.  
TOTAL SAMPLE 
(4200 women) 














The VOICE Study: What it will look like 
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Why ARV-based prevention? 
 
Anti-retroviral (ARV) drugs have changed the HIV/AIDS pandemic, allowing people with 
HIV/AIDS to live longer and more productive and healthy lives.  They have also been used for 
prevention, such as by health workers who have been exposed to HIV, an approach known as 
post-exposure prophylaxis, and most widely for preventing mother-to-child transmission 
(PMTCT).  
 
Pre-exposure prophylaxis, or PrEP, is an HIV 
prevention approach that typically involves the 
daily use of oral ARVs by people who are HIV-
negative.  The idea is that taking a medicine 
every day would prevent infection if HIV should 
enter the body, such as through sexual 
intercourse.  
 
Two ARVs that are already widely used for 
treatment, tenofovir and Truvada, are being 
evaluated in different HIV prevention PrEP 
trials. The VOICE Study will be looking at  
both ARVs as well as an ARV-based 
microbicide called tenofovir gel.  Tenofovir  
gel is also already being studied separately. 
 
Both tenofovir and Truvada have strong safety 
profiles as an effective drug that is well tolerated 
by most people, meaning that the drug causes 
minium side effects.  However, ARV-based 
microbicides and PrEP also present new 
challenges for the field, and many advocates  
did not hesitate to raise the burning questions 
surrounding potential for drug resistance.  
 
Potential for resistance to ARV-based prevention approaches  
 
Anti-retrovirals are effective drugs for extending the lives of people living with HIV/AIDS. 
Some people with HIV/AIDS, especially those who do not take the drugs everyday as prescribed, 
can form drug resistance—making the drugs ineffective at fighting the virus.  People are 
concerned and want to know what this could mean for healthy, HIV-negative individuals who 
may be using anti-retrovirals everyday as a prevention method. 
 
The fact is, we do not yet know if ARV-based microbicides could increase the chances of 
resistance to ARVs in trial participants who become infected with HIV during or following the 
VOICE Study.  While it is a possibility, researchers hope that a number of measures being 
worked into the study design will help mitigate any possible risk.  
 
 
Learning the different names, doses and 
forms of the VOICE Study’s ARV products   
Tenofovir and Truvada, the brand name for a 
combination drug consisting of tenofovir 
disoproxil fumarate (TDF) and emtrictabine 
(FTC), are a type of ARV called nucleotide 
reverse transcriptase inhibitors (NRTIs).  
 
Tenofovir, known by the brand name Viread, is 
taken as treatment as a 300 mg tablet once a day.  
Truvada, sometimes referred to as tenofovir+FTC, 
is a tablet containing 300 mg of tenofovir and 200 
mg of FTC and is also taken once a day.  As 
approved drugs for the treatment of HIV/AIDS, 
each is considered a first-line treatment for people 
starting anti-HIV drug therapy and each is used in 
combination with other products.  
 
Tenofovir gel contains the same active ingredient 
in the oral form of the drug.  It is an attractive 
candidate microbicide because it specifically 
targets HIV.  In its current formulation, each dose 
of tenofovir gel contains approximately 40 mg of 
active drug.  
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For example, all participants will receive monthly HIV testing7 so that investigators can quickly 
identify women who have become infected with HIV while in the study and immediately stop 
their use of the study product (topical gel or oral pill).  These and other procedures are intended  
to minimize as much as possible ARV exposure by a woman who has become infected.  Limiting 
exposure will help decrease the selection of drug resistance and reduce potential problems with 
treatment in the future.  
 
Drug resistant virus has an advantage only in the presence of the ARV, so that’s why it is 
important to minimize exposure.  However, nothing is certain until the trial is conducted and 
results are known.  The dilemma here is that, although resistance is a concern, it is unknown the 
extent to which it will be a factor in HIV prevention trials.  At this point, researchers believe the 
benefits of such a trial outweigh the risk of resistance.  
 
Prevention package and standard of care 
 
At the time of this consultation, the VOICE Study planned to provide all study participants with 
free laboratory tests and physical exams, counselling on preventing HIV infection and free male 
condoms.  STI risk-reduction counselling, testing and treatment will be provided at no charge to 
both women and their partners.  VOICE Study participants who acquire HIV will be linked with 
appropriate services and care in the study site communities. 
                                                
7 There was an extensive discussion on the form of HIV testing to be used during recruitment for the VOICE trial. 
Some advocates wanted every woman to receive a PCR (Polymerase chain reaction) test at screening, which is 
highly accurate and would eliminate the window period and chance that an HIV-positive woman could enter the 
study. However, the current protocol calls for PCR only at the end of the trials, as the cost for multiple PCR tests is 
prohibitive. Researchers promised to look into the possibility of changing the protocol.  
 
Commonly Asked Questions about ARV-based HIV prevention approaches 
 
Will ARV resistance be a problem?  
• We don’t know yet. No scientific or clinical information is available about the nature of 
resistance or the incidence of resistance among those using vaginal gel or oral ARVs for 
prevention.  
 
Will those who get infected have HIV that is resistant to the PrEP ARVs or ARV-based microbicide? 
• We don’t know anything for sure, but researchers will monitor women monthly for HIV 
infection and will stop the study products immediately if infection is detected. 
• In monkey studies, the virus that is initially transmitted is usually not drug-resistant, but 
resistance does become more likely with time if the PrEP ARV is continued. 
 
Will this affect their subsequent care and choice of ARV treatment? 
• Some research suggests that resistant virus may be overtaken by sensitive virus within weeks 
of stopping ARVs for PrEP. 
• In mothers who took single dose nevirapine for pMTCT and developed nevirapine resistance, 
there was no decrease in response to ARV treatment if it was initiated after 6 months. 
• But we don’t know if this will be the same for PrEP. 
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While the prevention package met essential standards, some advocates urged for additional 
services, including free female condoms and pap smears, to be offered at all of the trial sites. 
Following the advocates’ consultation and a consultation MTN had with its Community Working 
Group, the VOICE team has decided to provide funds to its sites to purchase approved male and 
female condoms for study participants.  In regard to pap smears, the researchers note it is 
extremely difficult to provide pap smears at all of the sites because most sites do not have the 
pathologists available to read them.  
 
It’s never too early to think about post-trial access 
 
Although the study is still in a pre-trial planning phase, questions around post-trial access arose. 
In South Africa, advocates have been fighting for years to get oral tenofovir included in the 
national guidelines’ first line treatment regimen for people living with HIV/AIDS.  As this drug 
is still not readily available for life-saving treatment purposes, advocates questioned the 
feasibility that it could be accessible if proven effective for prevention purposes.  Should the 
VOICE Study show encouraging results, issues surrounding access will become more pressing.  
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NEXT STEPS: RECOMMENDATIONS AND ACTION ITEMS  
 
The relationship between researchers and advocates has often been marked by tension, distrust 
and suspicion.  While at times this sentiment is born from real experience, often suspicion 
evolves more from the absence of any avenue for communication, than because of real 
transgressions.  As researchers and advocates strengthen their relationships and allow for open 
dialogues, they increasingly realize that the two groups have the same interests at heart—to 
find effective and empowering ways to help women and men prevent HIV infection.  
 
We conclude this report by identifying the main action items each group asked of each other.  
We hope that advocates and researchers will undertake these steps to help strengthen each 
other’s ability to serve the field, build stronger bridges between advocates and scientists, and 
contribute to the growing HIV prevention research advocacy movement.  
  
What advocates asked of researchers  
 
Research literacy: There was an overwhelming consensus that more opportunities should be 
provided to gain and strengthen advocates’ understanding about how clinical trials and HIV 
prevention research work.  Specifically, groups recognised a need for training on substantive 
issues, such as how clinical trials are conducted and how microbicides work, and skills-building 
trainings focused on technical issues, such as how to read a trial protocol.  
 
Civil society consultation at all stages of trial development: Advocates appreciated being 
consulted early on in the development process of the VOICE Study and hope it sets a precedent 
for future clinical trials.  Likewise, they want to stay informed throughout trials, not just at the 
time when results are disseminated. 
  
Support in securing funding for advocacy: International advocacy groups are exploring more 
ways to funnel funds to local and grassroots groups working in study communities.  These funds 
could include small and easily accessible grants for immediate and ongoing microbicide 
advocacy, or identifying opportunities to include microbicides in existing and larger grant 
proposals.  Research groups can support these efforts by letting funders know the important role 
that advocates play in supporting and improving HIV prevention research. 
 
Ongoing consultation with other advocacy groups: Recommendations were made for cross-
group training and site visits to build networks and capacity.  There was a suggestion that a 
global Community Advisory Board (CAB) be formed that would advise and consult with HIV 
prevention research groups.  
 
What researchers asked of advocates 
 
Constructive input and substantive feedback: Researchers are open to consulting with 
advocates and sharing protocols.  In return, they request that advocates provide constructive 
ideas and input on issues such as, which kind of HIV test to use during the screening process and 
how to disseminate trial results in communities.  It is easy to criticize a trial, but what is really 
needed are advocates willing to roll up their sleeves and help in ways that enable trials to be 
conducted as efficiently and ethically as possible. 
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Ideas on improving adherent use of the trial product: One of the main challenges currently 
faced in HIV prevention research trials, and especially microbicides studies, is the issue of 
consistent use of the product.  Many studies have found that participants either do not use the 
product or falsely report the extent to which they use the product.  Poor adherence can impact 
and skew the outcomes of a study, which leads to inconclusive or incorrect trials results.  
 
Scientists are actively looking for new ways to improve women’s adherence through better and 
more rigorous adherence counselling, and finding new ways for women to privately report 
product use for more accurate data analysis.  Researchers welcome input and ideas from 
advocates who have a close ear to the ground and may be able to provide insight into the 
difficulties women have with adherence and how to address these circumstances.  
 
Advocacy for affordable prices and effective regulatory processes: As more and more 
products enter Phase III trials, researchers will increasingly need support and assistance from 
advocates, who can help put pressure on government regulatory bodies and groups holding 
patents, to ensure speedy licensure and access to scientifically-proven products.  
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SPONSORING RESEARCH GROUPS 
 
 
MICROBICIDE TRIALS NETWORK 
 
The Microbicide Trials Network (MTN) was established in 2006 by the National Institute of 
Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), as 
the newest of six NIAID-funded HIV/AIDS clinical trials networks.  With co-funding from the 
National Institute of Mental Health and the National Institute of Child Health and Human 
Development, both NIH institutes, the MTN brings together international investigators and 
community and industry partners who are devoted to reducing the sexual transmission of HIV 
through the development and evaluation of microbicides, working within a unique infrastructure 
specifically designed to facilitate research required to support licensure of topical microbicide 
products for widespread use.  MTN is guided by an agenda that aims to complement rather than 
duplicate the research programs of its global research partners.  It also seeks participation by and 
collaborations with representatives of diverse scientific disciplines related to HIV prevention, as 
well as from the lay communities where MTN trials are being conducted. www.mtnstopshiv.org 
 
POPULATION COUNCIL  
 
The Population Council conducts research worldwide to improve policies, programs, and 
products in three areas: HIV and AIDS; poverty, gender, and youth; and reproductive health.  
The goal of the HIV and AIDS program is ambitious: to arrest the spread of the HIV epidemic in 
developing countries and to enable people to mitigate or eliminate the impact of HIV on their 
own health, and on their families, communities, and societies.  To achieve these goals, the 
Council brings its wide array of capabilities, including basic research in immunology; the 
development and introduction of an effective microbicide; social science and health-related 
research to understand better the social, behavioural, and biomedical aspects of HIV and AIDS; 
the formulation of evidence-based policies; and the development, evaluation, and scale-up of 
effective service-delivery models. www.popcouncil.org  
 
 
CO-CONVENING ADVOCACY GROUPS 
 
 
AFRICAN MICROBICIDES ADVOCACY GROUP  
 
Launched at the 2004 International Microbicides Conference, the African Microbicides 
Advocacy Group (AMAG) is a regional network that leads a co-ordinated African engagement in 
setting and moving forward the international microbicides advocacy and research agenda. 
AMAG works towards the availability of, access to, and use of, an expanded range of woman-
initiated HIV prevention options.  It seeks to advance the recognition of the legitimacy of 
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AIDS VACCINE ADVOCACY COALITION 
 
Founded in 1995, the non-profit AIDS Vaccine Advocacy Coalition (AVAC) seeks to create a 
favourable policy and social environment for accelerated ethical research and eventual global 
delivery of AIDS vaccines and other prevention methods as part of a comprehensive response to 
the pandemic. www.avac.org 
 
This work is guided by the following principles: 
 
 Translate complex scientific ideas to communities AND translate community needs and 
perceptions to the scientific community. 
 Manage expectations. 
 Hold agencies accountable for accelerating ethical research and development. 
 Expand international partnerships to ensure local relevance and a global movement. 
 Ensure that policy and advocacy are based on thorough research and evidence. 
 Build coalitions, working groups and think tanks for specific issues. 
 Develop and widely disseminate high-quality, user-friendly materials. 
 
AIDS AND RIGHTS ALLIANCE FOR SOUTHERN AFRICA 
 
Established in 2002, the AIDS and Rights Alliance for Southern Africa (ARASA) is a regional 
partnership of non-governmental organisations working together to promote a human rights 
approach to HIV/AIDS in Southern Africa through capacity building and advocacy.  It is 
constituted in the form of a trust and all partner organisations are members of the trust.  Three 
steering committees, comprising trust members, act as advisory boards for the three ARASA 
programme areas: training and awareness raising, advocacy and lobbying and regional treatment 
literacy and advocacy.  ARASA seeks to achieve its primary objective through: Advocacy and 
lobbying; training and awareness raising; and capacity building for access to treatment and 
prevention. www.arasa.info 
 
GLOBAL CAMPAIGN FOR MICROBICIDES 
 
The Global Campaign for Microbicides is a broad-based, international effort to build support 
among policymakers, opinion leaders, and the general public for increased investment into 
microbicides and other user-controlled prevention methods.  Through advocacy, policy analysis, 
and social science research, the Campaign's diverse network of over 285 NGOs works to 
accelerate product development, facilitate widespread access and use, and protect the needs and 
interests of users, especially women.  The Campaign Secretariat is housed at PATH, an 
international, nonprofit organization that improves the health of people around the world.  
www.global-campaign.org 
 
Specifically, the goals of the Campaign are to: 
 Raise awareness and mobilise political support for increased funding for microbicide 
research, female condom and cervical barrier methods;  
 Create a supportive policy environment for the timely development, introduction and use 
of new prevention technologies; and  
 Ensure that as science proceeds, the public interest is protected and the rights and 
interests of trial participants, users, and communities are fully represented and respected. 
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